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Abstract
Both IgG and secretory IgA Abs in mucosal secretions have been implicated in blocking the earliest
events in HIV-1 transit across epithelial barriers, although the mechanisms by which this occurs
remain largely unknown. In this study, we report the production and characterization of a human
rIgA2 mAb that carries the V regions of IgG1 b12, a potent and broadly neutralizing anti-gp120 Ab
which has been shown to protect macaques against vaginal simian/HIV challenge. Monomeric,
dimeric, polymeric, and secretory IgA2 derivatives of b12 reacted with gp120 and neutralized CCR5-
and CXCR4-tropic strains of HIV-1 in vitro. With respect to the protective effects of these Abs at
mucosal surfaces, we demonstrated that IgG1 b12 and IgA2 b12 inhibited the transfer of cell-free
HIV-1 from ME-180 cells, a human cervical epithelial cell line, as well as Caco-2 cells, a human
colonic epithelial cell line, to human PBMCs. Inhibition of viral transfer was due to the ability of
b12 to block both viral attachment to and uptake by epithelial cells. These data demonstrate that IgG
and IgA MAbs directed against a highly conserved epitope on gp120 can interfere with the earliest
steps in HIV-1 transmission across mucosal surfaces, and reveal a possible mechanism by which b12
protects the vaginal mucosal against viral challenge in vivo.
Transmission of HIV-1 occurs primarily through sexual contact and breastfeeding in which
mucosal surfaces of the genital or gastrointestinal tracts, respectively, are exposed to HIV and/
or HIV-infected cells (1,2). For successful infection to occur, infectious virus must breach the
mucosal barrier consisting of stratified squamous or columnar epithelial cells and gain access
to target cells permissive for viral uptake and replication (3,4). Once within the mucosa, HIV-1
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establishes both local and systemic viral reservoirs with devastating immunological
consequences, including depletion of CD4+ memory T cells and immunodeficiency (5,6).
Moreover, viral reservoirs are resistant to eradication by the cellular and humoral arms of the
immune system and by antiviral therapies. The development of strategies to reduce sexual
transmission of HIV-1 requires a better understanding of immunological factors that are
capable of interrupting attachment, uptake, and transfer of HIV-1 by mucosal epithelial cells.
Evidence from macaque models of simian/HIV (SHIV)5 infection indicates that Abs directed
against envelope spike glycoproteins (i.e., gp120 and gp41) are capable of conferring mucosal
defense against HIV-1 (7–10). The most well-characterized anti-envelope Ab in this regard is
IgG1 b12, one of only a handful of human mAbs known to be capable of neutralizing a broad
range of primary HIV-1 isolates (11–13). IgG1 b12 recognizes a highly conserved epitope on
gp120 involved in binding to CD4 (14). Macaques administered IgG1 b12 i.v. or topically (i.e.,
intravaginally) were protected against SHIV infection by the vaginal route (15,16). The
mechanism(s) by which IgG1 b12 inhibited viral infection of the vaginal mucosa was not
determined in these experiments, but it is generally assumed that the Ab interferes with virus-
host cell contact.
In humans and macaques, mucosal secretions contain a mixture of IgG and secretory IgA
(SIgA) Abs (17). In secretions of the female genital tract, IgG and SIgA are found at roughly
equal concentrations, whereas in the gastrointestinal tract, IgG concentrations are 30- to 100-
fold lower than SIgA (1,18–20). SIgA is a polypeptide complex that consists of two (or more)
IgA monomers joined at their C termini by a J chain that is covalently associated with secretory
component (SC), a 70-kDa glycoprotein derived from the polymeric IgR during transcytosis
across epithelial cells (21). Although both IgG and SIgA are capable of neutralizing viruses in
mucosal secretions (22), the relative contribution of one Ab type over another in blocking
sexual transmission of HIV-1 remains to be determined.
To better understand the mechanisms by which Abs against gp120 confer mucosal immunity
to HIV, we have produced and characterized a recombinant human IgA2 mAb that carries the
H and L chain variable domains of Ab b12. We demonstrate that monomeric and dimeric forms
of recombinant human IgA2 b12 react with gp120 and neutralize HIV-1 infection of T cells.
More importantly, we report that both IgG1 b12 and IgA2 b12 can prevent HIV-1 attachment,
uptake, and transfer by cervical and intestinal epithelial cells. These data demonstrate that both
IgG and IgA Abs against gp120 can interfere with the earliest steps in HIV-1 transmission
across mucosal surfaces and reveal a possible mechanism by which IgG1 b12 protects the
vaginal mucosa against viral challenge in vivo.
Materials and Methods
Construction of mammalian expression vector-encoding IgA2 b12
The plasmid pSM102 (see Fig. 1) encoding IgA2 b12 was constructed from pDR12 (12) by
replacing the IgG1 constant domains with the IgA2 constant domains. The genomic DNA
encoding human IgA2m (1) was amplified as a single 1.5-kb SacI-SalI DNA fragment by PCR
using plasmid pcDNA3: cα2m (1) as template (23) and custom-designed primers 5′-
GTCATCGTGAGCTCATCCCCGACCAGCCCCAAGGTG-3′ and 5′-
TTTGACGTCGACTTTCCCAAGTGCTGAGACCCTGAGGAT-3′). The underlined
sequences indicate the engineered restriction sites, and the bold sequences indicate the
IgA2m1 coding region. The IgA2 constant domain was fused in-frame with the b12 VH coding
sequence.
5Abbreviations used in this paper: SHIV, simian/HIV; SIgA, secretory IgA; SC, secretory component; GS, glutamine synthetase; GMEM,
glutamine-free MEM; AI, affinity index; TCID50, 50% tissue culture-infective dose; MSX, methionine sulfoximine.
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Establishment of stable CHO cell lines secreting monomeric and dimeric/polymeric forms of
IgA b12
We used the selectable-amplifiable marker, glutamine synthetase (GS) encoded on plasmid
pSM102 (see Fig. 1), to produce stable cell lines secreting high levels of IgA b12. The use of
GS as a selectable-amplifiable marker has been described previously (12,24). CHO-K1 were
seeded into 6-well cell culture plates and maintained in glutamine-free MEM (GMEM;
Mediatech) containing 5% FCS (HyClone) and methionine sulfoximine (MSX; Sigma-
Aldrich) at a range of concentrations (20 –120 μM). Supernatants of pSM102-transfected cells
were screened by ELISA for the presence of IgA Abs reactive with gp120 (see below). Cells
from positive wells were collected by trypsinization and cloned three times by limiting dilution
(25). A single clone secreting monomeric IgA2 b12, herein referred to as 100-02-C9, was
chosen for further study based on a number of criteria, including levels of Ab production and
stability in culture.
To produce cell lines secreting dimeric IgA2 b12, clone 100-02-C9 was transfected with
plasmid pcDNA3Hygro::J chain encoding human J chain and selected for growth in GMEM-
MSX medium containing hygromycin (400 μg/ml) (23). We identified transfectants secreting
polymeric forms of IgA2 b12 by screening cell supernatants using a SC-binding ELISA (26).
Two stable transfectants, J2 and J10, were cloned three times by limiting dilution and used for
further studies.
Clone 100-02-C9 was maintained in GMEM supplemented with 5% FCS (Ultra Low Bovine
IgG FBS; Invitrogen Life Technologies) and 80 μM MSX (Sigma-Aldrich). Clone J1 secreting
was maintained in the same medium with the addition of hygromycin B (400 μg/ml). Large
scale cell culture was performed using 10-layer CellStacks (Corning).
Immunoprecipitation and Western blot analysis of IgA2 b12
Supernatants from CHO cell lines (~3 ml) were mixed with polyclonal goat anti-human α-
chain antiserum (Cappel/ICN) followed by protein G agarose beads (Pierce), which bind goat
IgG but not human IgA (27). Protein G agarose beads (~40 μl) were collected by centrifugation
and resuspended in 2× Laemmli sample buffer, boiled for 5 min, and then subjected to SDS-
PAGE on 4 –18% gradient gel (Bio-Rad). The proteins were transferred to a polyvinylidene
difluoride membrane (0.45-μm pore size; Bio-Rad) by electroelution and then probed with
biotin-labeled goat anti-human IgA Fab (1/5000) (Tago Immunologicals) and avidin-HRP
(Sigma-Aldrich). Membranes were developed using the ECL kit (Amersham Pharmacia) and
exposed to Kodak X-OMAT film (Fisher-Scientific). When necessary, polyacrylamide gels
were stained with Gel Code Blue (Pierce) to visualize proteins.
Purification of monomeric and dimeric forms of IgA2 b12
Abs were affinity purified from cell culture supernatants using ImmunoPure Immobilized
Protein L (Pierce), which binds human κ L chains, and then were subjected to size exclusion
chromatography by a Sephacryl S300 High Resolution column (GE Healthcare) to separate
dimeric and monomeric forms of IgA2 b12. The column was calibrated using the following
molecular mass standards: dextran 2000 kDa, ferritan 440 kDa, catalase 220 kDa, and RNase
A 10 kDa. Peak fractions of IgAb2 were pooled and purity was checked by SDS-PAGE and
concentrations of the IgA molecular forms were determined by ELISA and absorbance
spectroscopy (28).
Expression of recombinant human rSC
rSC was produced by transfection of CHO-K1 cells with pCL-2, a plasmid encoding human
rSC provided to us by J. Woof (University of Dundee Medical School, Dundee, Scotland; Refs.
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29–31). Transfectants were identified by hygromycin B (200 μg/ml; Roche). Stable clones
secreting rSC were isolated by limiting dilution and assayed for expression of rSC by ELISA.
gp120 ELISA
HIV-1-specific ELISAs to detect IgA b12 were done by coating Nunc Maxisorp 96-well
microtiter plates (Fisher-Scientific) with HIV-1IIIB lysate (Calypte Biomedical) or
rHIV-1IIIB gp120 (ImmunoDiagnostics) using 100 ng of protein/well in PBS (pH 7.4). After
overnight incubation, plates were blocked with PBS plus BSA (1% w/v) and Tween 20 (0.1%)
before the addition of IgA b12 or IgA b12 cell culture supernatants. The plates were washed
and then probed with peroxidase-conjugated, affinity-purified goat polyclonal Abs (0.5 μg/ml)
specific for human IgA (Southern Biotechnology Associates) or human κ-chain (Sigma-
Aldrich). Plates were developed using the one-component tetramethylbenzidine substrate
(Kirkegaard & Perry) and read using a spectrophotometer (Molecular Devices). Total IgA
levels were determined by sandwich ELISA using plates coated with goat anti-human IgA
(Cappel) diluted 1/1000 into PBS and detected using biotin-labeled goat-anti-human, as done
previously (18). Human IgA2 (Calbiochem) was used as a standard.
Ab-binding curves
Ninety-six-well microtiter plates (Corning) were coated with HIV-1MN gp120 (2 μg/ml in PBS
(pH 7.4); Immunodiagnostics) overnight at 4°C. The plates were blocked with 4% nonfat dry
milk for 30 min at room temperature and then incubated for 2 h at 37°C with serial dilutions
of mAbs. The plates were developed by incubation with alkaline phosphatase-labeled goat anti-
human κ L chain Abs and the alkaline phosphatase substrate kit (Pierce), then analyzed using
a microtiter plate spectrophotometer set at 405 nm. The concentrations of mAbs that gave an
OD of 1.0 at 405 nm were used for the avidity determination and competitive inhibition assays
(see below).
Ab avidity and affinity for gp120
The avidity (or functional affinity) of each form of b12 mAb was determined by disrupting
mAb binding to the solid-phase Ag using increasing amounts of ammonium thiocyanate
(NH4SCN; 0 – 4.0 M), a mild denaturing agent for 30 min after mAb binding to the solid phase,
before adding the labeled conjugate Ab, as described (32,33). The affinity of each form of b12
mAb was measured by competitive inhibition of Ab binding to the solid phase by preincubation
of mAb (concentration yielding OD of 1.0) with serial 3-fold dilutions of soluble HIV-1MN
gp120 Ag (0 –1 μg/ml) overnight at 4°C, as previously described (34–36). The amounts of un-
bound mAbs were measured as described above. For both the NH4SCN and competitive
inhibition assays, the ODs in duplicate wells were averaged; the background with no Ag was
subtracted. The molar concentrations yielding a 50% inhibition of OD with inhibitor or soluble
Ag were determined as the affinity index (AI) and competitive inhibition index, respectively.
The latter was used to estimate the dissociation constant (KD) using the formula KD = a0((A0/
A0 − A) − 1) as described (34).
HIV-1 neutralization assays
HIV-1BaL (R5) and HIV-1IIIb (X4) were obtained through the National Institutes of Health
AIDS Research and Reference Reagent Program (NIH ARRRP; nos. 510 and 398,
respectively). For conventional neutralization assays, viruses (50 50% tissue culture-infective
dose (TCID50)/ml) were mixed with IgG1 or IgA2 b12 (monomeric, dimeric, and polymeric
forms) and then added in duplicate to 96-well flat-bottom microtiter plates (Costar) and
incubated for 30 min at 37°C. PBMCs from healthy adult donors seronegative for HIV-1 and
hepatitis B and C were isolated from buffy coats by Ficoll-Hypaque gradient centrifugation.
Before infection, PBMCs were activated by overnight incubation with PHA (5 μg/ml; Sigma-
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Aldrich) in RPMI 1640 with 10% heat-inactivated FBS (HyClone), 5% recombinant human
IL-2 (Roche), and 50 μg/ml gentamicin (Invitrogen Life Technologies) at 37°C and 5% CO2.
The cells were then washed and cultured for 3 days in RPMI 1640 with 10% FBS and 5% IL-2
before being added to the virus-Ab mixtures. A total of 2 × 105 cells in 100 μl were added to
each well and incubated for 2 h at 37°C to permit viral infection. The PBMCs were washed
three times to remove unbound virus, and 6 days later the cell supernatants were assayed for
p24 levels by ELISA (Beckman Coulter).
Neutralization activity of the various forms of Ab b12 was confirmed using HIV-1 envelope-
pseudotyped viruses, which are capable of single-round replication generated by cotransfection
of 293T cells with the pNL4-3.luc.RE vector (N. Landau, NIH ARRRP) and the psVIIIex7
env-expressing vector, provided by J. Sodroski (Dana-Farber Cancer Institute) (37). The assays
were conducted by seeding U87.CD4.CCR5 cells (NIH ARRRP) in totals of 1.5 × 104 cells/
well in a 96-well flat-bottom tissue culture-treated plate (Corning). Seeded cells were contained
in a 100-μl volume of medium (DMEM containing 10% FBS, 300 μg of G418/ml, glutamine,
and penicillin-streptomycin) and incubated for 24 h at 37°C in 5% CO2. Separately, Ab and
virus mixtures were made by adding 60 μl of serially diluted Ab in medium to an equal volume
of medium containing 2 × 105 relative light units of pseudotyped virus and incubated for 1 h
at 37°C. Following incubation, 100 μl of the Ab and virus mixtures were transferred to the U87
cells and incubated for 3 days at 37°C in 5% CO2. Cell lysates were generated by adding 60
μl of cell culture lysis reagent (Promega), incubated at room temperature for 5 min, pelleted
by centrifugation at 1200 × g for 2 min. A total of 20 μl of lysate was transferred to opaque
assay plates (Corning), luciferase reagent was added (Promega), and luciferase activity was
measured on a luminometer (Orion; Berthold Detection Systems). The degree of virus
neutralization by Ab was determined by measuring luciferase activity. The percent
neutralization at a given Ab concentration was express as: ((luciferase activity in the absence
of Ab − luciferase activity in the presence of a given Ab concentration)/luciferase activity in
the absence of antibody) × 100. The following molecular masses were used to calculate the
molar concentration of each Ab (Table I): IgG1 150 kDa; mIgA2 170 kDa; dIgA2 (with J chain)
360 kDa; SIgA2 b12 (with J chain and SC) 430 kDa. The molecular mass of pIgA2 b12, which
is a mixture of monomer, dimer, and higher molecular mass molecules, was assumed to be 320
kDa, the dominant species expressed by clone J1 expressing pIgA2 b12 as determined by gel
filtration chromatography.
Epithelial cell transfer of HIV-1 to PBMCs
ME180 (HTB-33; American Type Culture Collection (ATCC)) and Caco-2 (HTB-37; ATCC)
cells were cultured in Eagle’s MEM supplemented with 10% FBS, 100 U/ml penicillin, and
100 μg/ml streptomycin (Invitrogen Life Technologies). For the HIV-1 transfer assays, ME180
and Caco-2 epithelial cells were plated in 96-well flat-bottom microtiter plates at 1 × 105 cells/
ml (200 μl/well) 2 days before infection. HIV-1BaL or HIV-1IIIb (50 TCID50/ml) were
incubated in the absence or presence of IgG1 or IgA2 b12, or relevant isotype control Abs for
30 min at 37°C. The virus-Ab mixtures were then applied to confluent epithelial cell
monolayers and incubated for 2 h at 37°C. The monolayers were washed three times with
medium to remove any unbound virus and overlaid with activated PBMCs (2 × 105/well in
200 μl). Cell-free supernatants were harvested 6 days after coculture and assessed for p24 levels
by ELISA. For studies aimed at determining at which step(s) b12 inhibits viral transfer from
epithelial cells to PBMCs, mAbs were added 1) concurrently with HIV-1BaL or HIV-1IIIb (50
TCID50/ml; designated +/−), 2) after epithelial cells had been washed to remove free virus
(designated −/+), virus-Ab complexes, or free Ab; 3) or at both steps (designated +/+).
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Inhibition of HIV-1BaL attachment and internalization by ME180 cells
We used a protocol adapted from Bobardt et al. (38) to measure HIV-1 attachment and uptake
by human cervical ME180 cells. Briefly, ME180 cells grown to confluence in 96-well flat-
bottom plates were exposed in duplicate to HIV-1BaL (20 ng p24/well) in the absence or
presence of IgG1 or IgA2 b12, or relevant isotype control Abs. Cell monolayers were washed
twice to remove free virus and virus Ab complexes, and then treated with lysis solution
(Beckman Coulter). Levels of p24 Ag were measured in cell lysates by ELISA. The p24 Ag
levels were considered representative of the total amount of cell associated virus (i.e., virus on
the cell surface, as well as virus that had bee internalized). To determine only the amount of
virus internalized by ME180 cells, the monolayers were washed two times to remove free,
unbound virus, and then treated with 0.05% trypsin-EDTA (Invitrogen Life Technologies) for
8 min at 37°C to proteolytically remove surface-bound virus (39–41). Preliminary dose-
response curves revealed that 0.05% trypsin resulted in the maximal removal of virus from the
cell surfaces: higher concentrations of trypsin did not reduce HIV-1 levels further. After
treatment with trypsin, the cells were treated with lysis solution and lysates were tested for p24
Ag, as described above.
Results
Production of monomeric and dimeric forms of recombinant human IgA2 b12
Ab IgG1 b12 was originally engineered from a Fab by cloning the b12 VH and VL genes into
a mammalian combinatorial expression vector (12). Using this original vector, we switched
the isotype of b12 by replacing the IgG1 constant domains with a PCR fragment encoding the
constant domains of human IgA2(m1) (23), resulting in the plasmid pSM102 (Fig. 1). Plasmid
pSM102 was then transfected into CHO cells, and several cell lines were established which
secreted mIgA2 b12 into cell supernatants. One cell line in particular, 100-02-C9, was chosen
for further study because of its stability and robust production of Ab. Clone 100-02-C9 was
adapted to protein/serum-free medium and mIgA2 b12 was purified from cell supernatants by
protein L affinity chromatography. Analysis of purified mIgA2 b12 by nonreducing SDS-
PAGE revealed a protein species of ~150 kDa, which corresponds to the expected molecular
mass of mIgA2 b12 (Fig. 2A).
To produce dimeric/polymeric forms of IgA2 b12, clone 100-02-C9 was supertransfected with
plasmid pcDNA3Hygro::J chain, encoding human J chain (23). We identified several stable
cell lines, notably J2 (“clone 1”) and J10 (“clone 2”), which secreted high molecular mass (i.e.,
dimeric and/or polymeric) forms of IgA2 b12. Total IgA2 b12 present in the supernatants of
J2 cell cultures, which contain a mixture of monomers, dimers, and higher molecular mass
polymers, were purified by protein L affinity column and referred to simply as “polymeric”
IgA2 b12 (pIgA2 b12). Dimeric forms of IgA2 b12 were purified from higher molecular forms
IgA2 b12 by size-exclusion chromatography (Fig. 2B). As expected, dimeric IgA2 migrated
with an apparent molecular mass >220 kDa (Fig. 2A). Additional minor bands of slightly higher
and lower molecular masses (e.g., 200 –250 kDa) were also evident by SDS-PAGE, and likely
represent dIgA2 b12 with varying degrees of glycosylation (42). Western blot analysis
confirmed that J chain was associated with dIgA2 b12, but not mIgA2 b12 or IgG1 (Fig. 2C).
Additionally, IgA2 b12 derived from clones J2 and J10 (but not from 100-02-C9) were capable
of binding to human SC in a SC solid phase-binding assay (Fig. 3), further demonstrating that
J chain was properly incorporated into dimeric/polymeric forms of IgA2 b12. It should be
underscored that the use of the term polymeric IgA2 b12 in this manuscript refers to a mixture
of monomers, dimmers, and higher molecular mass polymeric forms of Ab.
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Reactivity of IgA b12 with gp120
We used ELISA to confirm that the different forms of IgA2 b12 retained their ability to bind
gp120. The use of anti-κ chain-specific secondary Abs in our ELISAs enabled us to directly
compare the binding profiles of different Ab isotypes (i.e., IgA and IgG). As shown in Fig.
4A, all three forms of IgA2 b12 (monomeric, dimeric, and polymeric) reacted with gp120MN
in a dose-dependent manner with binding profiles similar to that obtained with IgG1 b12.
Identical results were obtained when ELISAs were performed using gp120IIIB and
gp120JR-FL (data not shown).
To assess the relative avidity (i.e., functional affinity) of different forms of IgA2 b12 for gp120,
we determined the amount of ammonium thiocyanate required to elute 50% mAb bound to
gp120 (32,33). From this, we calculated the AI for each mAb preparation, as described in
Materials and Methods. All three forms of IgA b12 eluted from the plate at roughly equivalent
amounts of ammonium thiocyanate (0.2– 0.6 M), thereby yielding similar AIs (Fig. 4B).
Although slightly higher levels of ammonium thiocyanate were required to IgG1 b12, this
difference was not significant. The relative affinities of each form of IgA b12 as estimated
using a competitive inhibition assay were also similar (Fig. 4C). From these experiments, we
conclude that monomeric and dimeric forms of IgA2 b12 recognize gp120 at levels comparable
to IgG1 b12.
Neutralization of HIV-1 by IgA2 b12
We next examined the ability of different forms of IgA2 b12 to inhibit CCR5-tropic and
CXCR4-tropic strains of HIV-1 from infecting PBMCs. Monomeric, dimeric, and polymeric
forms of IgA2 b12 demonstrated a dose-dependent inhibition of HIVBaL (CCR5-tropic) and
HIVIIIB (CXCR4-tropic) infection of PBMCs similar to that obtained with IgG1 b12 (Fig. 5).
No significant differences in the IC50 were observed among the different Abs tested in this
assay. We also performed pseudovirus infection assays, which are considerably more sensitive
than conventional T cell infection assays (37). Three pseudoviruses were tested: HIV-1JR-FL
and HIV-1JR-CSF, two CCR5-tropic virus isolates, and HIV-1HxB2, a CXCR4-tropic virus
which is virtually the same as HIVIIIB. These studies revealed subtle differences in
neutralization activities among the different derivatives of b12 (Table I). These differences
were most apparent when mAbs were examined as a function of their molar concentrations
used in the neutralization assays, and when we compared IC90 values, rather than the less
stringent IC50 values. For example, monomeric IgA2 b12 was notably less effective than other
forms of b12 at neutralizing HIV-1JR-FL and HIV-1JR-CSF, whereas it was no different at
neutralizing HxB2 (Table I). In fact, all forms of IgA2 b12 were rather poor at neutralizing
HIV-1JR-CSF for reasons that are not immediately apparent. In contrast, monomeric, dimeric,
and polymeric forms of IgA2 b12 were slightly more effective than IgG1 at neutralizing
HIV-1HxB2.
We were also successful in producing a small amount of purified dimeric IgA2 b12 complexed
with human SC (A. Hessell and D. Burton, manuscript in preparation) that enabled us to
examine the capacity of SIgA2 b12 to neutralize HIV-1. As shown in Table I, the IC50 and
IC90 for SIgA2 b12 were slightly lower than those obtained with dIgA2 b12, suggesting that
the addition of SC may marginally enhance the capacity of IgA b12 to block HIV-1 infection
of T cells.
Inhibition of HIV-1 transfer from epithelial cells to PBMCs
Although cervical epithelial cells are not considered permissive for HIV-1 infection per se,
they may facilitate virus transfer to other cell types within the mucosa (2,41). To determine
whether Ab b12, which is directed against a highly conserved epitope within the CD4-binding
site of gp120, can interfere with this step in viral transmission, we incubated HIV-1BaL and
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HIV-1IIIb with IgG1 b12, or IgA2 b12, and then applied the mixtures to monolayers of ME180
cells, a human-derived cervical epithelial cell line, or Caco-2 cells, a human-derived intestinal
epithelial cell line. HIV-1 “transfer” from epithelial cells to CD4+, chemokine receptor+ cells
was assessed by the addition of activated PBMCs to the epithelial cell monolayers. p24 levels
were measured in the supernatants of the cocultures 6 days later (see Materials and
Methods). We found that IgG1 b12, as well as monomeric and dimeric forms of IgA2 b12,
inhibited HIV-1 infection of PBMCs in both the cervical and colonic epithelial cell transfer
assay (Fig. 6). To discern whether the mAbs were interfering with viral attachment to and/or
uptake by the epithelial cell monolayers (“step 1”), or inhibiting viral transfer from epithelial
cells to PBMCs (“step 2”), the transfer assay was modified such that Ab b12 was added
concurrently with HIV-1BaL and HIV-1IIIb (as done above), or added after virus had been
allowed to attach to, and be internalized by, epithelial cells. As shown in Fig. 7, the addition
of IgG1 b12 or dimeric IgA2 b12 at either step 1 (+/−), step 2 (−/+), or both (+/+) prevented
HIV-1 infection of PBMCs, indicating in fact that b12 can block viral attachment of epithelial
cells, as well as epithelial-PBMC transfer. Similar concentrations of Ab b12 were required to
inhibit step 1 or step 2 of the epithelial transfer assay. It should be noted that at much higher
doses of challenge virus (~4000 TCID50/ml), Ab applied before viral attachment to epithelial
cells was more efficient at blocking infection of PBMCs than was Ab added after epithelial
attachment/uptake (data not shown). Thus, b12 can act at either step in the epithelial transfer
assay, but appears more efficient when added before viral epithelial exposure.
Inhibition of HIV-1 attachment to and uptake by cervical epithelial cells
In primary intestinal epithelial cells, it was reported that HIV-1 is internalized by endocytosis
before being transferred to CD4+, co-receptor+ cells permissive for viral replication (4). From
our experiments, it was unclear whether Ab b12 in step 1 was interfering with virus attachment
to epithelial cells, and/or blocking virus uptake (i.e., endocytosis) into epithelial cells. To
differentiate between attachment and uptake, we modified our transfer assays to include a
trypsin digestion step which allowed us to proteolytically inactivate virus bound to cell
surfaces, but not affect viruses that had been endocytosed (39–41). Both IgG1 b12 and IgA2
b12 demonstrated a dose-dependent reduction in the total amount of HIV-1BaL associated with
ME180 cells (Fig. 8). In contrast, control IgG1 or IgA2 Abs had no effect on virus-epithelial
interactions. Treatment of HIV-1-exposed ME180 cells with trypsin revealed that ~50% of the
total cell-associated virus was resistant to digestion, suggesting that a fraction of HIV-1 was
located intracellularly. The amount of HIV-1 recovered from trypsin-treated ME180 cells was
reduced when HIV-1BaL was treated with IgG1 b12or IgA2 b12, inferring that b12 is capable
of inhibiting virus uptake, as well as virus attachment to cervical epithelial cells.
Discussion
Understanding the molecular mechanisms by which IgG and IgA Abs against gp120 interfere
with HIV-1 transmission across mucosal surfaces has important implications for the design of
effective vaccines and topical antivirals. In this study, we have successfully produced and
purified recombinant monomeric and dimeric human monoclonal IgA2 Abs carrying the V
regions of gp120-specific Ab b12 and characterized their functional activity in vitro. Human
J chain was properly associated with dimeric IgA2 b12 as evidenced by Western blot analysis
and by the ability of dimeric IgA2 b12 to bind human SC in a solid phase-binding assay.
Although dimeric/polymeric forms of IgA can occur in the absence of J chain, these complexes
cannot bind SC (43). rIgA2 b12 recognized gp120 by ELISA and neutralized HIV-1 infection
of both activated PBMC and in a T cell line at levels comparable to IgG1 b12, indicating that
both monomeric and dimeric forms of IgA2 b12 are fully functional. Finally, we have
demonstrated for the first time that both IgG1 and IgA2 b12 are capable of preventing HIV-1
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attachment to and uptake by colonic and cervical epithelial cells, revealing a possible
mechanism by which Ab b12 protects mucosal compartments from HIV-1 infection in vivo.
Although two studies have demonstrated the ability of IgG1 b12 to protect macaques against
mucosal SHIV challenge, the mechanism by which Ab b12 neutralized HIV-1 in vivo was not
determined (15,16). Results from our current study indicate that Ab b12 is capable of interfering
with the earliest steps in mucosal transmission of HIV-1; attachment to and uptake by epithelial
cells. These data are somewhat surprising because b12 recognizes an epitope overlapping the
CD4-binding site on gp120, and the interaction of HIV-1 with epithelial cells is independent
of CD4 (2,4). Indeed, neither Caco2 nor ME180 epithelial cells express CD4 as detected by
immunofluorescence or flow cytometry (E. N. Janoff and J. Palaia, unpublished data).
Therefore, it is likely that Ab b12 interferes with viral attachment by steric hindrance or altering
virus-host cell interactions through other means (44). Several groups have proposed that
galactosyl ceramide serves as the primary receptor for HIV-1 on intestinal epithelial cells
(45,46). Galactosyl ceramide is a glycosphingolipid that protrudes only a few nanometers from
the plasma membrane, so occupancy of IgG or IgA b12 on the surface of gp120 would be
expected to interfere with virus-membrane contact. Although the receptor used by HIV-1 on
cervical epithelial cells is currently unknown, the virus-epithelial cell interaction most certainly
involves gp120.
Two other broadly neutralizing anti-HIV-1 human Abs, 2F5 and 2G12, have been class
switched from IgG1 to IgM and IgA1 (47). 2G12 binds a conserved cluster of oligomannose
side chains on gp120, and 2F5 targets a membrane proximal region of gp41. The neutralization
activities of 2F5 and 2G12 were unchanged by isotype switching, except for 2G12 IgM, which
inhibited HIV-1 infection of PBMCs ~28 times more efficiently than corresponding IgG
(47). Whereas we converted Ab b12 to a human subclass IgA2, Wolbank et al. (47) converted
2G12 and 2F5 to subclass IgA1. IgA1 and IgA2 (of which there are two allotypic variants, m1
and m2) are found at roughly equal concentrations in mucosal secretions of the female genital
tract and the large intestine (48). Although slight structural differences exist between IgA1 and
IgA2 (e.g., IgA1 has an extended hinge region as compared with IgA2), there are currently no
known functional differences between the two subclasses (17). In another report, Liu et al.
(49) isotype switched the human mAb F425B4e8 from an IgG2 to other IgG subclasses (i.e.,
IgG1,3,4), as well as IgA1. mAb F425B4e8 recognizes an epitope at the base of the V3 loop
of gp120 (50). Overall, the isotype variants of F425B4e8 performed similarly to each other
with respect to recognition of gp120 and HIV-1 neutralization activity in vitro.
The feasibility of producing large amounts of IgA2 b12 in cell culture may have a number of
practical applications. Most notable is the possibility of including IgA2 b12 in a topical
microbicide aimed at reducing HIV-1 transmission across the mucosal surfaces of the vagina
and ectocervix. In macaque models, IgG1 b12 applied vaginally in PBS or in a hydroxymethyl
cellulose gel protected animals against a vaginal SHIV challenge, although protection was
short-lived and required relatively high concentrations of Ab (16). We postulate that IgA2 b12,
when complexed with SC, may provide better passive protection than that afforded by IgG1
b12 because SIgA is protease resistant and has a propensity to anchor in the mucus layer
overlying epithelial cell surfaces (21). In fact, studies are underway to investigate the potential
of SIgA2 b12 as a topical microbicide in the macaque model. Another application of IgA2 b12
is as a standard in ELISAs designed to detect anti-HIV-1 IgA Abs in human secretions.
Accurately measuring anti-viral IgA titers in mucosal secretions is inherently difficult, and has
been plagued, in part, by variation in ELISAs from laboratory to laboratory (20). Providing
IgA2 b12 as a standard to public health and research laboratories would better enable the results
of ELISAs from different laboratories around the world to be compared.
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Determining the role of IgG and SIgA in conferring immunity to HIV-1 on mucosal surfaces
has implications for HIV vaccine design and delivery. SIgA Abs are induced almost exclusively
following mucosal vaccination, and are not elicited at any appreciable levels by systemic (e.g.,
i.m.) immunizations (1,51). Whereas mice are considered to have a “common” mucosal
immune system (i.e., immunization at one mucosal site stimulates a SIgA response at both
local and both distant local mucosal responses), in humans, the shared mucosal immune system
is more restricted. For example, oral immunization stimulates Abs in the proximal small
intestine, but not in the distal large intestine or female genital tract (18). However, Abs in the
female genital tract can be induced following vaginal or more practically intranasal
vaccination. Delivery of mucosal vaccines also poses significant challenges, including the need
for better adjuvants and formulations capable of withstanding the harsh environment of the
respiratory and gastrointestinal tracts. The availability of fully functional IgG1 and IgA2 Abs
that have identical V regions directed against a conserved neutralizing epitope on gp120 will
enable us to define experimentally in animal models the “division of labor” that certainly exists
between these two different Ab isotypes in mucosal tissues.
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FIGURE 1.
Schematic of the IgA2 b12 expression vector. Plasmid pSM102 encodes the IgA1 b12 VH and
VL (κ) chain, GS, as a selectable-amplifiable marker in mammalian cells, and β-lactamase for
selection in Escherichia coli.
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FIGURE 2.
Expression and purification of monomeric and dimeric forms of IgA2 b12. A, Nonreducing
SDS-PAGE analysis of monomeric, dimeric, and polymeric forms of IgA2 b12, as compared
with IgG1 b12. Ab preparations were size-fractionated by nonreducing SDS-PAGE and stained
with Coomassie blue. Monomeric IgA2 b12 migrated with a molecular mass of ~150 kDa (filled
arrowhead), whereas higher molecular mass forms (>220 kDa; open arrowheads) were present
in the dimeric and polymeric IgA b12 preparations. A protein band of ~50 kDa was present in
all IgA b12 preparation (*), and likely corresponds to κ L chain dimers that dissociate from
intact Ig (52). IgG1 b12 migrated with a molecular mass of ~160 kDa. B, Separation of dimeric
and monomeric forms of IgA2 b12 by FPLC gel filtration. As described in Materials and
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Methods, Abs were eluted from by isocratic elution on HiPrep 16/60 Sephacryl S-300 High
Resolution column at a flow rate of 0.5 ml/min. Peaks containing dimeric IgA2 b12 (50.02
peak) and monomeric IgA2 b12 (61.52 peak) were determined by ELISA and SDS-PAGE. The
following molecular mass standards were used to calibrate the column: dextran 2000 kDa,
ferritan 440 kDa, catalase 220 kDa, and RNase A 10 kDa. C, Anti-J chain Western blot analysis.
Monomeric, dimeric, and polymeric forms of IgA2 b12, as well as IgG1 b12, were subjected
to nonreducing SDS-PAGE, transferred to nitrocellulose, and probed with an anti-human J
chain Ab. The minor band observed in the IgG1 b12 lane is probably due to spill over from
the adjacent pIgA2 b12 sample.
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FIGURE 3.
SC associates with polymeric IgA2 b12. Microtiter plates were coated with polyclonal goat
anti-human IgA Abs, and then overlaid with human secretory IgA (positive control),
monomeric IgA2 b12 (negative control), or dimeric IgA2 b12 from CHO cell clones J2 or J10.
The plates were then probed with human SC and then developed using anti-human SC Abs.
Each data point represents the average of two microtiter wells tested in parallel.
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FIGURE 4.
Reactivity, avidity, and affinity of IgA2 b12 for gp120. The relative reactivity, avidity, and
affinity of different forms of purified IgA2 b12 were compared with IgG1 b12. A, ELISA
analysis examining the reactivity IgA2 and IgG1 b12 with gp120MN. Anti-human κ chain Abs
were used as secondary reagents to allow direct comparison of reactivity of different b12
isotypes with gp120. B, Functional avidity of IgA2 and IgG1 b12 for gp120MN as determined
by ammonium thiocyanate dissociation (see Materials and Methods). The AI (inset) is defined
as the amount of ammonium thiocyanate (M) required to elute 50% of the Ab from gp120.
C, The relative affinities of IgA2 and IgG1 b12 for gp120MN were determined indirectly by
competitive inhibition. Abs were mixed with increasing concentrations of soluble gp120MN
before being applied to ELISA plates coated with the same Ag. The amount of soluble gp120
required to reduce Ab binding by 50% was defined as the competitive inhibition index (inset,
left). The approximate KD (inset, right) was determined as described in Materials and
Methods.
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FIGURE 5.
Neutralization of HIV-1 infection of PBMCs by IgA2 b12. Monomeric, dimeric, and polymeric
(i.e., a mixture of monomers, dimers, and higher molecular mass polymers) IgA2 b12, as well
as IgG1 b12, at indicated concentrations were incubated with (A) HIV-1BaL or (B) HIV-1IIIb
for 30 min before being mixed with activated PBMCs. Levels of p24 in PBMC culture
supernatants were determined 6 days later by ELISA, as described in Materials and
Methods. Viral p24 in the control wells were consistently >14 ng/ml, confirming that the control
cells were productively infected with HIV. The mAb concentration (micrograms per milliliter)
necessary to inhibit 50% of viral infection, referred to as the IC50, is indicated in the inset.
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FIGURE 6.
Inhibition of HIV-1 transfer from epithelial cells to PBMC target cells by b12 mAbs. Cell-free
HIV-1BaL or HIV-1IIIb preparations were incubated with IgG1 or IgA2 b12, and then applied
to confluent monolayers of ME180 cells (left, A and B) or Caco-2 cells (right, C and D). Transfer
was assessed by the addition of activated PBMCs and measuring p24 levels in culture
supernatants by ELISA. The IC50 (micrograms per milliliter) is indicated in the inset table.
Isotype-matched control Abs of irrelevant specificities showed no inhibition of HIV-1 transfer
(data not shown).
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FIGURE 7.
b12 mAbs block inhibition of HIV-1 transfer from epithelial cells to PBMCs. Cell-free
HIV-1BaL or HIV-1IIIb preparations applied to confluent monolayers of ME180 cells (left, A
and B) or Caco-2 cells (right, C and D) were incubated with IgG1 or IgA2 b12: 1) before
epithelial exposure (+/−); 2) after epithelial exposure and washing but before addition of
PBMCs (−/+), or both times (+/+), and then transfer was assessed by the addition of activated
PBMCs and measuring p24 levels in culture supernatant by ELISA.
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FIGURE 8.
Inhibition of HIV-1 BaL internalization in ME180 cells by b12 mAbs. Increasing
concentrations of IgG1 or IgA2 b12 were mixed with HIV-1BaL before application to ME180
cells. After 1 h at 37°C, the cells were washed to remove unbound virus and then lysed. Levels
of p24 Ag in cell lysates were considered representative of the total amount of virus bound
specifically to cell surfaces, plus the amount of virus that had been internalized (□).
Alternatively, ME180 cells were treated with trypsin-EDTA (0.05%) for 8 min before lysis to
effectively remove virus bound to the cell surfaces. Levels of p24 Ag in cell lysates from
trypsin-treated cells were considered representative of the only amount virus internalized (■).
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